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Background. Optical coherence tomography (OCT) has facilitated characterisation of retinal alterations in MS patients. Only
scarce and in part conflicting data exists on diﬀerent MS subtypes. Objective. To analyse patterns of retinal changes in diﬀerent
subtypes of MS with latest spectral-domain technology. Methods. In a three-centre cross-sectional study 414 MS patients and 94
healthy controls underwent spectral-domain OCT examination. Results. Eyes of MS patients without a previous optic neuritis
showed a significant reduction of both retinal nerve fibre layer (RNFL) thickness and total macular volume (TMV) compared to
healthy controls independent of the MS subtype (P < 0.001 for all subtypes). RNFL thickness was lower in secondary progressive
MS (SPMS) eyes compared to relapsing-remitting MS (RRMS) eyes (P = 0.007), and TMV was reduced in SPMS and primary
progressive MS (PPMS) eyes compared to RRMS eyes (SPMS: P = 0.039, PPMS: P = 0.005). Independent of the subtype a more
pronounced RNFL thinning and TMV reduction were found in eyes with a previous optic neuritis compared to unaﬀected eyes.
Conclusion. Analysis of this large-scale cross-sectional dataset of MS patients studied with spectral-domain OCT confirmed and
allows to generalize previous findings. Furthermore it carves out distinct patterns in diﬀerent MS subtypes.
1. Introduction
Multiple sclerosis is an inflammatory and neurodegenerative
disorder of the central nervous system that leads to a progres-
sive axonal loss and degeneration of neurons. Whereas a vast
majority of MS patients present with a relapsing-remitting
disease course (RRMS) that may subsequently transforms
into secondary progressive MS (SPMS), a smaller portion of
patients shows a progressive course (PPMS) from the very
beginning of the disease [1].
Optical coherence tomography (OCT) is an increasingly
recognized, noninvasive tool in MS imaging that allows cost-
eﬀective investigation of the retina [2] in a disease in which
pathology of the anterior visual system is common. Over
the recent past, OCT has emerged as a potential marker of
axonal retinal degeneration in MS patients [3]. Of note, an
increasing number of studies have consistently shown an
association between OCT measures of retinal atrophy and
markers of degeneration derived from either structural mag-
netic resonance imaging or MR spectroscopy (MRS) studies
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[4–11] and between OCT measures and functional visual
parameters as well as physical disability and cognitive perfor-
mance [12–17]. Retinal nerve fibre layer (RNFL) thickness
and total macular volume (TMV) are the most frequently
investigated OCT parameters. They provide a unique oppor-
tunity to quantify the integrity of nonmyelinated axonal
tissue (RNFL) as well as all retinal layers (TMV), including
cellular segments, by a noninvasive imaging technique. RNFL
and TMV reduction can be detected in eyes with (MS-
ON) or without a previous history of optic neuritis (MS-
NON) applying diﬀerent OCT devices [15, 18–29]. Data on
distinct diﬀerences in OCT findings between MS subtypes
are scarce, and the results are at least in part conflicting.
In general, cross-sectional studies show a more profound
thinning of RNFL in progressive forms of MS compared
to RRMS patients. However, it remains unresolved to date
whether these diﬀerences are a genuine eﬀect of the disease
subtype per se or rather a function of disease duration, the
number of optic neuritis (ON) episodes in the patients’
history, or disease severity [30–34].
Most OCT studies previously performed in MS applied
time-domain technology. Only very recently spectral-do-
main technology became available which enables imaging
at substantially higher resolution without an increase in
scanning time [16, 22, 34–38]. Here we report results from
the largest multicentre cohort of MS patients and healthy
controls (HC) thus far, studied in three dedicated MS centres
in Germany, applying latest high-resolution spectral-domain
OCT (SD-OCT) technology. In this large cohort, we reliably
identified patterns of RNFL thinning and TMV reduction
among diﬀerent MS subtypes both with and without a
history of ON when controlling for disease duration and
severity, age, and gender.
2. Materials andMethods
2.1. Patients and Controls. 414 patients and 94 healthy con-
trols were recruited in three dedicatedMS units in the respec-
tive outpatient clinics at the Charite´ University Medicine
Berlin (NeuroCure Clinical Research Center (NCRC)), at
the Department of Neurology of the Heinrich-Heine Uni-
versity Du¨sseldorf (UKD) and in Hamburg (Institute for
Neuroimmunology and Clinical MS Research (inims)). Data
from a subgroup has previously been reported in Brandt
et al. [23]. Inclusion criteria were age between 18 and 60
years and a definite diagnosis of MS according to the revised
2005 McDonald criteria [39]. MS subtype classification in
RRMS, SPMS, or PPMS was based on the clinical course as
assessed by the treating physician using Lublin criteria [40].
A history of ON had to be clearly determinable either by
existing medical records, a VEP suggestive of optic neuritis,
or by patient self-reports. Only eyes in which a history of
ON could either be confirmed by clinical records or ruled
out were subsequently included in the analysis. Patients with
a refractive error of ≥5.0 diopters or with a history of eye
disease that may impact significantly on OCT measures (e.g.,
glaucoma, retinal disease, retinal surgery, and diabetes) were
excluded. Other exclusion criteria were acute optic neuritis
or any other acute relapse or steroid treatment less than six
months prior to OCT assessment as well as any other neuro-
logical disease with possible ocular manifestations. Disease
duration was calculated as time since diagnosis in months.
Participants were assessed in a clinical examination under
supervision of board certified neurologists within 6 months
of OCT. Extended disability status scale (EDSS) was calcu-
lated according to the current guidelines [41]. Time since
diagnosis was determined by reviewing patients’ medical
records. Healthy control participants were recruited from the
medical staﬀ, patients’ relatives, and other volunteers.
A total of 937 eyes (754 MS eyes and 183 HC eyes) were
finally included, 79 eyes were excluded from the analysis
either due to poor scan quality or incomplete clinical data,
in detail missing data on history of ON.
2.2. Ethics. The study protocol was approved by the local
ethics committee and was conducted in accordance with the
Declaration of Helsinki (1964) in its currently applicable
version, the Guidelines of the International Conference on
Harmonization of Good Clinical Practice (ICH-GCP) and
applicable German laws. All participants gave written in-
formed consent.
2.3. Optical Coherence Tomography. Participants underwent
SD-OCT examination using the Heidelberg Engineering
Spectralis SD-OCT (Heidelberg Engineering, Heidelberg,
Germany). For both eyes of each participant, RNFL thickness
around the optic disc was acquired using the 3.4mm circle
scan with the eye tracker system (TrueTrack) activated and
the maximum number of averaging frames in ART-MEAN
mode were tried to achieve. For assessing themacular volume
two diﬀerent scan protocols were used: the system built-in
macula scan (25 B-scans, scanning angle = 15◦× 15◦, ART =
9) was performed at the Hamburg and Du¨sseldorf sites,
while for the macular volume determination at the NCRC
a custom protocol (61 B-scans, scanning angle = 30◦× 25◦,
ART = 13) was used. Irrespective of the macular scan type,
the TMV was calculated using the device’s software. All scans
were performed by trained operators and were reviewed
for suﬃcient signal strength, correct centring, and beam
placement as well as segmentation. Only eyes that passed the
quality review were included in the subsequent analysis.
2.4. Statistical Analysis. Group comparisons of demographic
factors were analysed using Mann-Whitney U test (for age
and EDSS) and Pearson’s Chi-square test (for gender, alpha =
0.05). Within the MS cohort Spearman’s Rho analysis was
used for correlation of EDSS and disease duration.
Generalized estimation equation (GEE) models account-
ing for within-subject intereye correlations were applied to
test for diﬀerences of RNFL thickness and TMV between
the study cohorts. GEE models were corrected for age and
gender for the comparison of MS patients with HC and
additionally for disease duration for MS subtype analysis.
Associations of OCT with EDSS and regression analysis
of disease duration with RNFL thickness and TMV were
investigated with GEE models in a similar fashion. In all GEE
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Table 1: Demographic and clinical data of multiple sclerosis patients (MS) and healthy controls (HC). MS patients are subdivided in the
subtypes relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), and primary-progressive MS (PPMS).
HC MS
RRMS SPMS PPMS All MS
No. of Subjects
Total 94 308 65 41 414
Berlin 63 95 22 8 125
Hamburg 0 158 23 22 203
Du¨sseldorf 31 55 20 11 86
No. of Eyes (eyes with ON)
Total 183 561 (156) 116 (27) 77 (0) 754 (183)
Berlin 122 187 (77) 44 (15) 16 (0) 247 (92)
Hamburg 0 270 (54) 35 (2) 41 (0) 346 (56)
Du¨sseldorf 61 104 (25) 37 (10) 20 (0) 161 (35)
Gender
Male (%) 31 (33) 87 (28) 29 (45) 24 (59) 140 (34)
Female (%) 63 (67) 221 (72) 36 (55) 24 (41) 274 (66)
Age (in years)
Mean (SD) 34.47 (10.25) 39.10 (9.50) 48.23 (6.11) 46.90 (7.10) 41.31 (9.59)
Range 19–56 19–58 33–59 32–59 19–59
Disease duration (in months)
Mean (SD) NA 91.05 (80.26) 186.15 (87.94) 100.02 (93.33) 106.87 (89.51)
Range NA 0–384 39–403 4–426 0–426
EDSS
Median NA 2.0 5.5 4.0 2.5
Range NA 0-7 3-8 2-8 0-8
models OCT measurements were included as the dependent
variable. All statistical analyses were performed with R
(R Version 2.12.2) including the geepack package for GEE
models. Statistical significance was established at P < 0.05.
3. Results
3.1. Cohort Description. An overview of the demographic
and basic clinical data including MS subtypes is given in
Table 1. Healthy controls showed no significant gender dif-
ferences to RRMS (Chi-square: P = 0.452) and SPMS (Chi-
square: P = 0.186) patients, while gender composition of
PPMS patients diﬀered compared to HC (Chi-square: P =
0.010). Mean age of HC was significantly lower compared
to all MS patients and all subtypes (Mann-Whitney U tests,
P < 0.001 for all subtypes). RRMS patients were significantly
younger than the progressive subtypes (Mann-Whitney U
tests, P < 0.001 for SPMS and PPMS). As a consequence, age
and gender were included as covariates in all GEE models.
Time since diagnosis of RRMS and PPMS was significantly
shorter compared to SPMS (Mann-Whitney U tests, P <
0.001 for both). Therefore, GEE models for MS subtype
comparison were additionally adjusted for disease duration.
Disease severity estimated by the EDSS was heterogeneous
between MS subtypes as evaluated by Mann-Whitney U tests
(RRMS versus SPMS: P < 0.001; RRMS versus PPMS: P <
0.001; SPMS versus PPMS: P = 0.03).
3.2. RNFL and TMV in MS-NON Eyes of Diﬀerent MS Sub-
types Compared to HC. For MS-NON eyes, diﬀerences in
RNFL thickness and TMV compared to HC are given in
Table 2. In summary, average peripapillary RNFL thickness
was reduced in the pooled cohort of all MS patients’ eyes
and in all MS subtypes compared to HC (Figure 1(a)).
Likewise, TMV was reduced for the pooled cohort of all
MS patients’ eyes and in all MS subtypes when compared
to HC (Figure 1(b)). All alterations of RNFL and TMV
in MS-NON eyes compared to control eyes showed strong
statistical significance based on GEE models (Table 2). EDSS
was inversely correlated with RNFL in case of all MS subtypes
without a history of prior ON (RRMS-NON: P = 0.007;
SPMS-NON: P = 0.034; PPMS-NON: P = 0.006). In
contrast, the TMV was only significantly correlated with the
EDSS in RRMS-NON eyes (P = 0.003), but not in SPMS-
NON (P = 0.321) or PPMS-NON (P = 0.085).
3.3. Comparison of MS-ON Eyes with MS-NON Eyes and HC.
Irrespective of the MS subtype, MS-ON eyes were signifi-
cantly diﬀerent from HC eyes for RNFL thickness and TMV
(Figure 2) and showed a more pronounced RNFL thinning
and TMV reduction when compared to MS-NON eyes
(Table 3). RNFL thickness of RRMS-ON eyes and SPMS-
ON eyes was significantly thinner compared to RRMS-NON
or SPMS-NON eyes, respectively. The same was true for
the TMV of ON-aﬀected MS eyes, which was significantly
reduced when compared to HC and to unaﬀected eyes of the
same MS subtype (Table 3, Figure 2). The extent of RNFL
thinning as well as TMV reduction was comparable between
RRMS-ON and SPMS-ON eyes (RNFL GEE: P = 0.369;
TMV GEE: P = 0.124). RRMS-ON eyes showed a significant
inverse correlation between EDSS and RNFL (P = 0.012)
while TMV did not reach significance (P = 0.085). For
SPMS-ON eyes no significant correlation of EDSS with OCT
parameters was found (RNFL: P = 0.169; TMV: P = 0.573).
3.4. Diﬀerences between Subtypes in MS-NON Eyes. Among
MS subtypes, RRMS patients showed less RNFL thinning
when compared to progressive subtypes (Table 2). When
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Table 2: OCT results for the subtypes of MS patients without a history of optic neuritis (NON). Total retinal nerve fiber layer (RNFL)
thickness (in µm) and total macular volume (TMV in mm3) are given as mean values with standard deviation (SD). Generalized estimation
equation (GEE) models were used to compare the MS cohorts to healthy controls. GEE models estimate the eﬀect size with standard error
(SE) and the respective P value.
GEE models comparing MS OCT parameters to the healthy control cohort
RNFL thickness TMV
Total RNFL
thickness
mean (SD)
[µm]
TMV
mean (SD)
[mm3]
Eﬀect Eﬀect size SE P value Eﬀect size SE P value
Group −9.571 1.177 <0.001 −0.235 0.043 <0.001
MS-NON
(n = 571)
90.15
(12.27)
8.48
(0.43)
Age −0.132 0.053 0.013 −0.006 0.002 0.002
Gender 2.272 1.116 0.042 −0.075 0.041 0.064
Group −8.470 1.188 <0.001 −0.197 0.044 <0.001
RRMS-NON
(n = 405)
92.03
(11.91)
8.54
(0.42)
Age −0.080 0.061 0.189 −0.003 0.002 0.094
Gender 2.933 1.224 0.017 −0.107 0.045 0.019
Group −9.951 1.084 <0.001 −0.248 0.039 <0.001
SPMS-NON
(n = 89)
83.14
(12.07)
8.32
(0.41)
Age 0.139 0.098 0.158 0.003 0.003 0.267
Gender −1.807 1.788 0.312 −0.150 0.062 0.015
Group −4.253 0.792 <0.001 −0.141 0.027 <0.001
PPMS-NON
(n = 77)
88.35
(11.31)
8.34
(0.42)
Age 0.037 0.093 0.691 −0.001 0.003 0.654
Gender 0.802 1.796 0.655 −0.044 0.064 0.492
Group N/A N/A N/A N/A N/A N/A
HC
(n = 183)
100.60
(9.41)
8.75
(0.34)
Age N/A N/A N/A N/A N/A N/A
Gender N/A N/A N/A N/A N/A N/A
adjusting GEE models for age, gender, and disease duration,
the only significant diﬀerence based on the mean total RNFL
thickness was found between RRMS and SPMS patients,
while patients with PPMS did not diﬀer from either RRMS
or SPMS (Table 4, Figure 1). As opposed to RNFL thickness
a diﬀerent pattern was obtained for TMVmeasures, in which
a significant reduction was found for SPMS and PPMS
when compared to RRMS patients. GEE models in which
we additionally corrected for EDSS to account for diﬀerent
stages of disease severity did not show diﬀerences in RNFL
thickness or TMV between MS subtypes (data not shown).
3.5. Association with Disease Duration and Yearly Atrophy
Estimate. GEE models were used to test for an association
of disease duration and RNFL thickness or TMV in MS eyes.
MS-NON eyes showed an association of RNFL thickness and
TMV with disease duration in the pooled cohort of all MS
subtypes (Table 5, Figure 3). This association was retained
in RRMS and SPMS eyes only for RNFL thickness and only
in RRMS eyes for TMV. In all MS subtypes the correlation
between RNFL thickness and TMV and disease duration was
lost in ON eyes (data not shown).
Based on the eﬀect size of the association of disease
duration and RNFL thickness or TMV we estimated RNFL
thinning and TMV reduction per year of ongoing disease
in MS-NON eyes only (Table 5). RRMS-NON eyes showed
the strongest and highly significant yearly changes for RNFL
thickness (−0.495 µm/year) and TMV (−0.0155mm3/year).
Interestingly, the significant yearly RNFL thinning in
SPMS-NON eyes (−0.464 µm/year) was not concomitantly
associated with a significant correlation in TMV change
(−0.0016mm3/year, P = 0.838). In contrast, PPMS-NON
eyes showed a less pronounced yearly RNFL thinning
(−0.105 µm/year) but in relation a distinct reduction of TMV
(−0.0111mm3/year). However, correlations of RNFL and
TMV with disease duration were not significant for PPMS-
NON eyes.
4. Discussion
Here we present the largest ever performed cross-sectional
study on retinal atrophy measures in MS subtypes applying
latest SD-OCT technology. Groups of disease subtypes in
our study were suﬃciently large to contrast findings in ON
versus ON-free eyes within subgroups. Hereby we show
that both RNFL and TMV are reduced in MS-NON eyes
versus HC when pooling all disease subtypes, but also
when separately comparing disease subtypes (RRMS, SPMS,
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Figure 1: Mean retinal nerve fibre layer (RNFL) thickness (a) and mean total macular volume (TMV) (b) for the healthy controls (HC) and
MS subtypes (RRMS, SPMS, and PPMS) without a history of optic neuritis (NON). Significant diﬀerences between the groups are indicated
with ∗(P < 0.05), ∗∗(P < 0.01), and ∗∗∗(P < 0.001), respectively.
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Figure 2: Mean retinal nerve fibre layer (RNFL) thickness (a) and mean total macular volume (TMV) (b) for the healthy controls (HC) and
MS subtypes (RRMS, SPMS) with a history of optic neuritis (ON). Significant diﬀerences between the groups are indicated with ∗(P < 0.05),
∗∗(P < 0.01), and ∗∗∗(P < 0.001), respectively.
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Table 3: OCT results for the subtypes of MS patients with a history of optic neuritis (ON). Total retinal nerve fiber layer (RNFL) thickness
(in µm) and total macular volume (TMV in mm3) are given as mean values with standard deviation (SD). ON eyes were compared to ON-
non aﬀected eyes of the same MS subtype using generalized estimation equation (GEE) models. GEE models estimate the eﬀect size with
standard error (SE) and the respective P value.
GEE models comparing OCT parameters between ON-aﬀected and unaﬀected eyes of the
same subtype
RNFL thickness TMV
Total RNFL
thickness
mean (SD)
[µm]
TMV mean
(SD) [mm3]
Eﬀect Eﬀect size SE P value Eﬀect size SE P value
Group −12.199 1.336 <0.001 −0.237 0.043 <0.001
MS-ON
(n = 183)
77.88
(14.61)
8.24
(0.45)
Age −0.147 0.056 0.008 −0.007 0.002 0.001
Gender 2.989 1.161 0.010 −0.041 0.040 0.299
Group −12.859 1.478 <0.001 −0.263 0.048 <0.001
RRMS-ON
(n = 156)
78.69
(14.91)
8.28
(0.45)
Age −0.087 0.066 0.185 −0.004 0.002 0.071
Gender 4.573 1.352 0.001 −0.048 0.046 0.295
Group −9.297 2.802 0.001 −0.252 0.100 0.012
SPMS-ON
(n = 27)
73.19
(11.89)
8.05
(0.41)
Age 0.419 0.216 0.052 0.009 0.008 0.234
Gender −7.310 2.591 0.005 −0.250 0.091 0.006
PPMS-ON
(n = 0) N/A N/A N/A N/A N/A N/A N/A N/A N/A
HC
(n = 183)
100.60
(9.41)
8.75
(0.34)
N/A N/A N/A N/A N/A N/A N/A
Table 4: Diﬀerences between MS subtypes without a history of optic neuritis (NON) were analyzed with generalized estimation equations
(GEE) models including age, disease duration, and gender as eﬀects.
GEE models comparing OCT parameters between NON eyes of diﬀerent MS subtypes
RNFL thickness TMV
Eﬀect Eﬀect size SE P value Eﬀect size SE P value
RRMS-NON versus SPMS-NON
Group −5.144 1.921 0.007 −0.137 0.066 0.039
Age 0.062 0.077 0.419 −0.001 0.003 0.775
Duration −0.044 0.009 <0.001 −0.001 0.0003 <0.001
Gender 1.864 1.377 0.176 −0.139 0.051 0.007
RRMS-NON versus PPMS-NON
Group −1.204 1.022 0.239 −0.104 0.037 0.005
Age −0.016 0.073 0.823 −0.002 0.003 0.371
Duration −0.034 0.008 <0.001 −0.001 0.0003 <0.001
Gender 2.785 1.393 0.045 −0.102 0.052 0.051
SPMS-NON versus PPMS-NON
Group 2.634 2.494 0.291 −0.053 0.090 0.553
Age 0.339 0.175 0.053 0.002 0.006 0.729
Duration −0.031 0.011 0.007 −0.001 0.0004 0.224
Gender −3.932 2.287 0.086 −0.127 0.086 0.139
and PPMS) to HC. Not surprisingly and in accordance
with previous studies, MS-ON eyes exhibited more severe
RNFL and TMV damage than MS-NON eyes. Both findings
have been previously described in a similar way by various
groups so that the nature of our study appears to be largely
confirmatory at first glance. However, our study has some
methodological advances compared to previous works that
have important implications for the interpretation of our and
previous OCT findings. The large sample size of our study
enabled a statistically robust comparison of various disease
subgroups with the inclusion of possible confounding factors
such as age, disease duration, and gender in the statistical
Multiple Sclerosis International 7
Table 5: Generalized estimation equation (GEE)models correlating disease duration with RNFL thickness and TMV, respectively. The yearly
change based on the eﬀect sizes of the respective GEE model.
RNFL thickness TMV
Eﬀect size SE P value
Change per year
(µm)
Eﬀect size SE P value
Change per year
(mm3)
All MS-NON −0.0444 0.0068 <0.001 −0.533 −0.0012 0.0002 <0.001 −0.014
RRMS-NON −0.0413 0.0088 <0.001 −0.495 −0.0013 0.0003 <0.001 −0.016
SPMS-NON −0.0387 0.0174 0.026 −0.464 −0.0001 0.0006 0.838 −0.002
PPMS-NON −0.0088 0.0151 0.562 −0.105 −0.0009 0.0006 0.131 −0.011
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Figure 3: Association of RNFL thickness (a) and TMV (b) with disease duration for RRMS, SPMS and PPMS subtypes in eyes without
previous optic neuritis. The blue lines indicate the 95%-, 50%- and 5%-quantiles.
models. In particular, we had larger numbers of patients
in the progressive subgroups (65 SPMS, 41 PPMS) than any
other previous study which allowed us to compare not only
disease subtypes with HC but also with each other. This is
of special interest against the background of the ongoing
scientific debate on distinct pathogenetic mechanisms in, for
example, PPMS versus RRMS. The subgroup comparisons
revealed a significant reduction of RNFL thickness in SPMS
patients versus RRMS after correction for age, gender, and
disease duration and a significant reduction of TMV in both
SPMS and PPMS patients versus RRMS.
In contrast, most previous works had only small sample
sizes, especially for progressive subtypes whichmay—besides
considerable diﬀerences in the statistical models—at least
partly explain the inconsistent findings. Pulicken et al.
(number of subjects: 135 RRMS, 16 SPMS, 12 PPMS, and
47HC) found only trends towards lower RNFL thickness
values in progressive disease versus RRMS and no diﬀerence
in TMV in progressive MS versus RRMS [30]. Henderson
et al. (number of subjects: 27 SPMS, 23 PPMS, and 20HC)
reported a significant reduction of RNFL and TMV versus
HC only in NON eyes from SPMS patients but not PPMS
patients and no diﬀerence between PPMS and SPMS [31].
Siepman et al. (number of subjects: 26 RRMS, 10 SPMS,
and 29 PPMS) could not detect diﬀerences between PPMS-
NON eyes and the pooled RRMS/SPMS-NON eyes [33].
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Serbecic et al. (number of subjects: 42 RRMS, 17 SPMS,
and 59HC) did not specifically address diﬀerences in OCT
measures between disease subtypes [34] as did numerous
other studies with highly heterogeneous patient populations
(Gordon-Lipkin et al. [6], number of subjects: 20 RRMS,
15 SPMS, 5 PPMS, and 15HC; Toledo et al. [12], number
of subjects: 7 CIS, 36 RRMS, 3 SPMS, 3 PPMS, 4 progressive-
relapsing, and 18HC; Fisher et al. [15], number of subjects:
90MS, 76 of whom RRMS, and 36HC; Sepulcre et al. [7],
number of subjects: 22 CIS, 28 RRMS, 5 SPMS, 6 PPMS, and
29HC), either because of insuﬃcient subgroup sample sizes
or owing to the fact that the study had goals other than
comparing disease subtypes.
In line with several previous studies [16, 30, 31, 42, 43]
we found higher RNFL measures in PPMS as compared
to SPMS (88.4 µm versus 83.1 µm), which is in striking
accordance with another study that also reported a diﬀerence
of approximately 5 µm between PPMS and SPMS-NON eyes
(93.9 µm versus 88.4 µm) [31]. Although these diﬀerences
were not significant in both studies, these findings may
point to a more severe RNFL damage in SPMS as compared
to PPMS, which is in line with the clinical features of
PPMS with a lower proportion of visual loss, less frequent
ON attacks, a predominant clinical involvement of the spinal
cord, and smaller brain lesions as compared to SPMS [31,
44, 45]. However, in contrast to Henderson et al. we found
like in SPMS a significant reduction of TMV in NON eyes
of PPMS patients versus RRMS and HC, which may display
the neurodegenerative component of PPMS concomitantly
reflected through brain atrophy measures [46].
Regarding the comparison of RNFL measures in RRMS
and SPMS patients, we made another interesting observa-
tion: as described previously by Costello et al. [32], dif-
ferences between SPMS-NON and RRMS-NON eyes were
about twice that of diﬀerences between SPMS-ON and
RRMS-ON eyes (∼20 µm versus ∼10 µm in Costello’s study,
∼10 µm versus ∼5 µm in our study). Costello et al. suggested
that the impact of prior ON may outweigh the eﬀects of
disease subtype.
Further limitation of most of the previous studies is
the utilization of time-domain OCT devices (TD-OCT) that
only allow for 2-dimensional retinal imaging, limiting its
use especially in the demanding macular investigations. The
newer high-resolution spectral-domain OCT allows spatial
imaging of the retina thus potentially greatly increasing the
accuracy and value of OCT in MS [35, 36, 47]. First studies
have already applied SD-OCTwith intraretinal segmentation
[16, 22, 26, 29]. Interestingly, the recent work by Saidha et
al. supports the finding of a more severe neuroaxonal retinal
damage in SPMS as compared to PPMS; a separate analysis
of the combined ganglion cell layer and inner plexiform
layer measured by Cirrus SD-OCT in diﬀerent MS subtypes
showed lowest values in SPMS [16]. In contrast, another
study by Albrecht et al. [29] applying manual segmentation
on Spectralis SD-OCT showed reduced measures in the
deeper inner nuclear layer of PPMS but not SPMS patients
versus HC. We presume that the ability of SD-OCT to
measure spatial scans (earlier TD-OCT had to interpolate
macular volume by using 6 radial linear scans) will in future
greatly increase the value of macular scans over the cur-
rently preferred peripapillary ring scans. In addition, spatial
scans allow for correction of positioning errors after scan
acquisition by limiting the analysed area to a subset of the
actual scan. For example, the Cirrus SD-OCT uses a spatial
scan for the peripapillary ring scan, allowing for subsequent
correction of alignment errors, whereas the Heidelberg
Engineering Spectralis facilitates an eye tracker function to
correct for eye movements. In TD-OCT, incorrect placement
of peripapillary ring scans accounts to a significant extent
for a weaker inter-measurement reliability and cannot be
corrected after the scan has been acquired [48]. Next to the
ability to analyse all intraretinal layers, improved test/retest-
reliability distinguishes SD-OCT from TD-OCT and makes
it an ideal instrument for the use in a longitudinal setting
where inter-measurement reliability is crucial [49].
The time course of RNFL thinning and TMV reduction
by atrophy of diﬀerent retinal layers—be it in the context of
ON or independent thereof—is an essential characteristic in
rating the usefulness of OCT as a potential marker of axonal
loss in longitudinal clinical trials. For MS-ON eyes it has
previously been shown that RNFL thinning occurs within
the first 6 months after the ON attack [21, 50]. Overall little
is known about temporal dynamics of retinal thinning in
MS-NON eyes. Based on published data from cross-sectional
studies in MS patients with diﬀerent disease duration a
rough estimate of the yearly atrophy rate appears to be
around 1 µm/year, which is ten times as much as what can
be expected from normal ageing [3]. In previous cross-
sectional studies significant inverse correlations of RNFL
thickness and disease duration could be established by
some authors [11, 15, 24], while others did not find a
significant correlation [20, 31]. In PPMS, an MS subtype
in which frequency of clinical attacks of ON is probably
lowest, Henderson et al. [31] estimated an RNFL thinning
of approximately 0.12 µm (TMV reduction: 0.01mm3) per
year of disease, which is in good agreement with our
results in PPMS eyes (RNFL thinning −0.105 µm/year;
TMV reduction: −0.011mm3/year). Correlations of OCT
measures of retinal atrophy and disease duration were not
significant for PPMS patients in both studies. In case of
RRMS and SPMS patients without ON we estimated higher
yearly RNFL changes than for PPMS (nearly 0.5 µm/year).
It is, however, important to note that yearly atrophy rates
are considerably lower than the optimized axial resolution of
SD-OCT devices, which is approximately 4–6 µm [51, 52].
This is of relevance in case OCT endpoints are taken into
consideration for future clinical trials, for example, in proof-
of-concept trials for neuroprotective agents. Depending on
the disease subtypes, model timelines and sample sizes have
to be planned accordingly.
In a first longitudinal OCT study by Talman et al. [53] a
thorough examination of the time course of RNFL thinning
in a mixed cohort of diﬀerent MS subtypes was performed
with TD-OCT (Stratus) revealing a yearly loss of approxi-
mately 2 µm in MS-NON eyes (GEE: P < 0.001). The study
included a preliminary sample size calculation (supplemen-
tary data of [53]) for future clinical trials that aimed to detect
a 30% reduction in the proportion of eyes with an RNFL
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thinning greater than the test-retest variability of the Stratus
OCT (6.6 µm) over a follow-up period of 2-3 years. With a
power of 80–90% and a type 1 error of 0.05, the authors’
sample size calculation estimated roughly a number of 400–
600 patients per group. The yearly loss of 2 µm reported by
Talman et al. from Stratus OCT is considerably higher than
the yearly reduction of approximately 0.5 µm calculated from
our dataset. Discrepancies may derive from the diﬀerences in
the devices applied (TD-OCT versus SD-OCT) and the fact
that our calculation is based on cross-sectional data only.
In sum, this study, based on a large SD-OCT data set,
confirms previous data on neuroaxonal retinal damage inMS
subtypes. At the same time, it extends previous findings by
providing new insights into diﬀerences between MS-ON and
MS-NON eyes in the various subgroups and—in addition—
allowing for reliable correction for non-disease-related fac-
tors such as age, gender disease duration, and severity.
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